Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ACLIV is a South Korean company commercializing antiviral and antibacterial surface-protection products, primarily films and coatings for touchscreens, handles, kiosks, mobile devices, vehicles, and medical-device surfaces. The company markets its technology as capable of rapidly reducing viral and bacterial contamination on treated surfaces and has highlighted certifications and regulatory clearances including ISO 21702 testing, CE marking, FDA-related claims, and a U.S. EPA registration for certain products. ACLIV appears to operate as both a brand and a corporate entity, while also being described in company materials as a business division associated with NEOTENY. Its business is centered on infection-control materials rather than therapeutic drug development, with commercialization focused on consumer, healthcare, and institutional surface applications. The company has reported collaborations with major enterprises and institutions, including pharmaceutical, medical-device, and NHS-related counterparties, although many partner names are not publicly disclosed.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ACLIV.